propyl 4-azidobenzoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: propyl 4-azidobenzoate
• 英文别名: Propyl 4-azidobenzoate
• 化学式: C₁₀H₁₁N₃O₂
• 分子量: 205.216
• InChiKey: OMRUTZOAHINMMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  40.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-乙炔基吡啶 、 propyl 4-azidobenzoate 在 噻吩-2-甲酸亚铜(I) 作用下， 以 甲苯 为溶剂， 反应 0.5h， 以96%的产率得到propyl 4-(4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl)benzoate
  参考文献：
  名称：

  A comparison of novel organoiridium(III) complexes and their ligands as a potential treatment for prostate cancer

  摘要：

  A range of 1,4-substituted 2-pyridyl-N-phenyl triazoles were synthesised and evaluated for their anti proliferative properties against lymph node cancer of the prostate (LNCaP) and bone metastasis of prostate cancer (PC-3) cells. Excellent-to-low IC50 values were determined (5.6-250 mu M), and a representative group of 4 ligands were then complexed to iridium(III) giving highly luminescent species. Re-evaluation of these compounds against both cell lines was then undertaken and improved potency (up to 72-fold) was observed, giving IC50 values of 0.36-11 mu M for LNCaP and 0.85-5.9 mu M for PC-3. Preliminary screens for in vivo toxicity were conducted using a zebrafish model showing a wide range of induced toxicity depending of the compound evaluated. Apoptosis and Caspase-3 levels were also determined and showed no statistical difference between some of the treated specimens and the controls. This study may identify novel therapeutic agents for advanced stage of prostate cancer in humans. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.12.035
• 作为产物：
  描述：

  对氨基苯甲酸 在 盐酸 、 硫酸 作用下， 以 水 、 乙腈 为溶剂， 反应 26.17h， 生成 propyl 4-azidobenzoate
  参考文献：
  名称：

  A comparison of novel organoiridium(III) complexes and their ligands as a potential treatment for prostate cancer

  摘要：

  A range of 1,4-substituted 2-pyridyl-N-phenyl triazoles were synthesised and evaluated for their anti proliferative properties against lymph node cancer of the prostate (LNCaP) and bone metastasis of prostate cancer (PC-3) cells. Excellent-to-low IC50 values were determined (5.6-250 mu M), and a representative group of 4 ligands were then complexed to iridium(III) giving highly luminescent species. Re-evaluation of these compounds against both cell lines was then undertaken and improved potency (up to 72-fold) was observed, giving IC50 values of 0.36-11 mu M for LNCaP and 0.85-5.9 mu M for PC-3. Preliminary screens for in vivo toxicity were conducted using a zebrafish model showing a wide range of induced toxicity depending of the compound evaluated. Apoptosis and Caspase-3 levels were also determined and showed no statistical difference between some of the treated specimens and the controls. This study may identify novel therapeutic agents for advanced stage of prostate cancer in humans. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.12.035

文献信息

• A comparison of novel organoiridium(III) complexes and their ligands as a potential treatment for prostate cancer
  作者：Samantha C. Hockey、Gregory J. Barbante、Paul S. Francis、Jarrad M. Altimari、Prusothman Yoganantharajah、Yann Gibert、Luke C. Henderson

  DOI：10.1016/j.ejmech.2015.12.035

  日期：2016.2

  A range of 1,4-substituted 2-pyridyl-N-phenyl triazoles were synthesised and evaluated for their anti proliferative properties against lymph node cancer of the prostate (LNCaP) and bone metastasis of prostate cancer (PC-3) cells. Excellent-to-low IC50 values were determined (5.6-250 mu M), and a representative group of 4 ligands were then complexed to iridium(III) giving highly luminescent species. Re-evaluation of these compounds against both cell lines was then undertaken and improved potency (up to 72-fold) was observed, giving IC50 values of 0.36-11 mu M for LNCaP and 0.85-5.9 mu M for PC-3. Preliminary screens for in vivo toxicity were conducted using a zebrafish model showing a wide range of induced toxicity depending of the compound evaluated. Apoptosis and Caspase-3 levels were also determined and showed no statistical difference between some of the treated specimens and the controls. This study may identify novel therapeutic agents for advanced stage of prostate cancer in humans. (C) 2015 Elsevier Masson SAS. All rights reserved.